Boundless Bio (BOLD) Stock Price, News & Analysis

Company Overview

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.

Key Stats

• Today's Range: $2.36 to $2.58
• 50-Day Range: $59.97 to $59.97
• 52-Week Range: $1.00 to $4.72
• Volume: 96,520 shs
• Average Volume: 102,520 shs
• Market Capitalization: $26.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Hold

Boundless Bio Stock Analysis - MarketRank™

Boundless Bio scored higher than 56% of companies evaluated by MarketBeat, and ranked 727th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Boundless Bio has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Boundless Bio has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Boundless Bio are expected to grow in the coming year, from ($3.85) to ($3.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Boundless Bio is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Boundless Bio is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Boundless Bio has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.91% of the float of Boundless Bio has been sold short.

Short Interest Ratio / Days to Cover

Boundless Bio has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Boundless Bio has recently decreased by 76.79%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Boundless Bio does not currently pay a dividend.

Dividend Growth

Boundless Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.91% of the float of Boundless Bio has been sold short.

Short Interest Ratio / Days to Cover

Boundless Bio has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Boundless Bio has recently decreased by 76.79%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Boundless Bio this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for BOLD on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Boundless Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

21.10% of the stock of Boundless Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

BOLD Stock Analysis - Frequently Asked Questions

How were Boundless Bio's earnings last quarter?

Boundless Bio, Inc. (NASDAQ:BOLD) issued its quarterly earnings results on Friday, May, 9th. The biotechnology company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.68) by $0.03.

When did Boundless Bio IPO?

Boundless Bio (BOLD) raised $100 million in an initial public offering (IPO) on Thursday, March 28th 2024. The company issued 6,250,000 shares at $16.00 per share.

What other stocks do shareholders of Boundless Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Boundless Bio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Alphabet (GOOG) and Visa (V).

Company Calendar

• Last Earnings: 5/09/2025
• Today: 7/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED-BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: NASDAQ:BOLD
• CIK: 1628738
• Web: www.audentestx.com
• Phone: 415-818-1001
• Fax: N/A
• Employees: 207
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Boundless Bio: $4.00
• High Price Target: $5.00
• Low Price Target: $3.00
• Potential Upside/Downside: +239.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$65.36 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -41.60%
• Return on Assets: -34.53%

Debt

• Debt-to-Equity Ratio: 0.35
• Current Ratio: 22.15
• Quick Ratio: 22.15

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.76 per share
• Price / Book: 0.17

Miscellaneous

• Outstanding Shares: 22,390,000
• Free Float: 17,663,000
• Market Cap: $26.42 million
• Optionable: No Data
• Beta: -1.34